A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation.
about
A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation.Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation.Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.New formulations of tacrolimus and prevention of acute and chronic rejections in adult kidney-transplant recipients.Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting DoseLong-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype.Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation.Impact of CYP3A5 genomic variances on clinical outcomes among African American kidney transplant recipients.Concepts of Genomics in Kidney Transplantation.Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.CYP3A genotypes of donors but not those of the patients increase the risk of acute rejection in renal transplant recipients on calcineurin inhibitors: a pilot study.Predictive Modeling of Tacrolimus Dose Requirements: "All That Is Gold Does Not Glitter".Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation.Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes.Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients.CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment.
P2860
Q38691788-E0161071-B2CB-4D69-9234-21CE2A191E58Q38704635-6C0A84FE-52B1-4815-936F-AAB4E0B35B4AQ38787174-7B2A0102-B5E0-4D00-BB26-2BDA6C3920D4Q38791651-B7A7E2B4-7F9F-4A9E-8A66-AE93560F56C8Q38809767-DC160433-02CA-40AA-AA1B-92B017EBF20BQ38865683-B4B80822-F52D-4F23-A1E8-E9A751FF1E47Q40750400-EC5FC895-3F0D-4380-B1B8-5775252DEA51Q42215557-413D0E26-D4C1-4826-9CD9-EE217D93094EQ46357849-FC36E7FD-7749-4C6F-A031-7DAA321C790EQ46684824-A44B813E-AFCF-409F-A4D2-877834D854C6Q47400761-8BB4770E-F83D-4D11-9D60-BD67355319A8Q48172244-9AEF659C-C161-48FF-9A9D-4FF4F7BAC16CQ48217119-FC52EFC6-B909-4403-BF10-8770AF066E7BQ48295034-1F89F6BF-BDAA-47B2-A539-B47D4C0630A9Q51262438-3574F8A9-4AB4-4941-92C1-70EBD4222C19Q52859440-04F1AAC5-79B9-49F5-9571-E4A133C86C37Q55280859-010FEC16-C43C-42A4-A29B-C33E5F2118A2
P2860
A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
A Randomized Controlled Trial ...... Donor Kidney Transplantation.
@en
A Randomized Controlled Trial ...... Donor Kidney Transplantation.
@nl
type
label
A Randomized Controlled Trial ...... Donor Kidney Transplantation.
@en
A Randomized Controlled Trial ...... Donor Kidney Transplantation.
@nl
prefLabel
A Randomized Controlled Trial ...... Donor Kidney Transplantation.
@en
A Randomized Controlled Trial ...... Donor Kidney Transplantation.
@nl
P2093
P2860
P356
P1476
A Randomized Controlled Trial ...... Donor Kidney Transplantation.
@en
P2093
A T Rowshani
D A Hesselink
J van de Wetering
M C Clahsen-van Groningen
R H N van Schaik
T van Gelder
P2860
P304
P356
10.1111/AJT.13691
P407
P50
P577
2015-12-29T00:00:00Z